<?xml version="1.0" encoding="utf-8" ?><rss version="2.0"><channel><title>Bing: Gender Validation in JavaScript</title><link>http://www.bing.com:80/search?q=Gender+Validation+in+JavaScript</link><description>Search results</description><image><url>http://www.bing.com:80/s/a/rsslogo.gif</url><title>Gender Validation in JavaScript</title><link>http://www.bing.com:80/search?q=Gender+Validation+in+JavaScript</link></image><copyright>Copyright © 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.</copyright><item><title>Persons of nonbinary gender may desire lower-dose testosterone ...</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2024/endo-2024-press-nolan</link><description>Among transgender and gender-diverse adults whose gender identity is nonbinary—not exclusively male or female—and who choose low-dose hormone treatment, most prefer to continue testosterone therapy at lower-than-recommended doses after at least six months of treatment, a new study finds.</description><pubDate>Fri, 31 May 2024 04:28:00 GMT</pubDate></item><item><title>AI model identifies patients at risk of underdiagnosed cause of high ...</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2026/lee-press-release-endo-2026</link><description>A study of a new AI model examining 30 years of routine electronic health records (EHR) data could improve screening for primary aldosteronism, a leading cause of high blood pressure that is often unrecognized but increases patients’ risk of cardiovascular complications, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.</description><pubDate>Sat, 13 Jun 2026 16:30:00 GMT</pubDate></item><item><title>Endocrine Society calls on Congress to address high insulin prices and ...</title><link>https://support.endocrine.org/news-and-advocacy/news-room/2022/endocrine-society-calls-on-congress-to-address-high-insulin-prices-and-consumer-out-of-pocket-costs</link><description>Members of Congress from both political parties have acknowledged access to affordable insulin is a problem. Rising costs have increased health disparities in the country and have particularly jeopardized the health of minorities, low-income individuals, people on high-deductible health plans, Medicare beneficiaries, and those who must transition from their parents’ insurance after turning 26.</description><pubDate>Wed, 14 Oct 2026 21:14:00 GMT</pubDate></item><item><title>Endocrine Society Statement in Support of Gender-Affirming Care</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2024/statement-in-support-of-gender-affirming-care</link><description>We stand firm in our support of gender-affirming care. Transgender and gender-diverse people deserve access to needed and often life-saving medical care.</description><pubDate>Tue, 07 May 2024 23:55:00 GMT</pubDate></item><item><title>AMA strengthens its policy on protecting access to gender-affirming ...</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2023/ama-gender-affirming-care</link><description>The American Medical Association (AMA) House of Delegates today passed the Endocrine Society’s resolution to protect access to evidence-based gender-affirming care for transgender and gender-diverse individuals.</description><pubDate>Sun, 11 Jun 2023 23:54:00 GMT</pubDate></item><item><title>Biological differences between females males need to be considered in ...</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2021/biological-differences-between-females-males-need-to-be-considered-in-scientific-studies</link><description>Biological differences between females and males affect virtually every aspect of medicine and biomedical research. In a new Scientific Statement released today, the Endocrine Society called for sex differences to be studied thoroughly to improve public health.</description><pubDate>Thu, 11 Mar 2021 15:12:00 GMT</pubDate></item><item><title>Asian patients more likely to develop type 2 diabetes 1 year after ...</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2024/endo-2024-press-niedzialkowska</link><description>One year after a prediabetes diagnosis, Asians were more likely to develop diabetes mellitus whereas Black patients were more likely to remain in prediabetes range, highlighting racial disparities in diabetes prevention, according to data presented at ENDO 2024, the Endocrine Society’s annual ...</description><pubDate>Tue, 28 May 2024 23:58:00 GMT</pubDate></item><item><title>Pregnant Women Who Sleep Less Than 7 Hours a Night May Have Children ...</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2024/pregnant-women-who-sleep-less-than-7-hours-a-night-may-have-children-with-developmental-delays</link><description>Pregnant women who do not get enough sleep may be at higher risk of having children with neurodevelopmental delays, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology &amp; Metabolism.</description><pubDate>Thu, 26 Sep 2024 13:07:00 GMT</pubDate></item><item><title>Consuming certain sweeteners may increase risk of early puberty</title><link>https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/chen-press-release</link><description>Consuming certain sweeteners commonly found in foods and beverages may increase the risk of early puberty in children, particularly among those who are genetically predisposed, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.</description><pubDate>Sat, 12 Jul 2025 23:59:00 GMT</pubDate></item><item><title>GLP-1 medications for type 2 diabetes and obesity may lower risk of ...</title><link>https://www.endocrine.org/news-and-advocacy/news-room/2024/endo-2024-press-nassar</link><description>Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.</description><pubDate>Fri, 31 May 2024 23:55:00 GMT</pubDate></item></channel></rss>